MedicineImmunologyInternal MedicineAutoimmunityImmunopathologyRheumatologyAutoantibodiesAutoimmune DiseasesConnective Tissue DiseasesConnective Tissue DisordersRheumatoid ArthritisSystemic Lupus ErythematosusAntibody Detection TestsAntibody Titer AnalysisAntinuclear Antibody PositivityAutoantibodies In Rheumatic DiseaseConnective Tissue Disease PathologyConnective Tissue InflammationExtractable Nuclear Antigen AntibodiesExtractable Nuclear Antigens
Twenty-three patients who lacked the full picture of mixed connective tissue disease (MCTD) initially, developed new findings or experienced regression of initial features with time. Each patient had at least 1 extractable nuclear antigen (ENA) antibody titer greater than or equal to 1:10,000 composed exclusively of ribonucleoprotein; but variation in titer occurred in 9 and Sm antibody was transiently found in 3 patients. Four initially had other diagnoses and negative antinuclear antibody tests (ANA) before developing speckled ANAs. Eleven patients had consistently speckled ANAs. As suggested by earlier clinical observations, MCTD can change clinically and serologically. This study demonstrates the sequential development of the features of SLE, polymyositis, rheumatoid arthritis and in addition emphasizes the serologic studies may also vary over time in these patients.